Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: i was sent a reply from investor relations , please read

Dear Mr. ,

Thank you fir your inquiry. The Company has had on embargo for a period of time a press release to address status matters. The Company expects to issue the release within approximately seven to ten days based on the culmination of certain events.

Please be advised the Company takes very seriously its disclosure decisions. Announcements are evaluated balancing the public’s desire for information against the occurrence or lack thereof of material events, the reporting requirements stipulated by law and regulatory agencies, and probably most underappreciated and highly applicable to Patriot at this time, the need to manage objectives associated with litigation and prospective settlement matters.

Sincerely,

PTSC IR

Note: This communication is intended to be confidential to the person addressed and is subject to protection under laws of copyright and the Electronic Communications Privacy Act. If you are not the intended recipient or the agent of the intended recipient or if you are unable to deliver this communication to the intended recipient, please do not copy or use this communication or show or disseminate it to any other person, but delete it from your system and notify the sender immediately by telephone at (760) 547-2700. Any applicable legal privilege is reserved and not waived by sending this communication.

Safe Harbor Statement: Statements herein which are not purely historical, including statements regarding Patriot Scientific Corporation's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risks and uncertainties associated with the litigation with TPL, and the uncertainties relating to the future of our MMP joint-venture . It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, and seasonality. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended May 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained herein. Patriot Scientific Corporation disclaims any obligation, and does not undertake to update or revise any forward-looking statements made herein.

Share
New Message
Please login to post a reply